Literature DB >> 12218394

Forty-one near full-length HIV-1 sequences from Kenya reveal an epidemic of subtype A and A-containing recombinants.

William E Dowling1, Bohye Kim, Carl J Mason, K Monique Wasunna, Uzma Alam, Lynne Elson, Deborah L Birx, Merlin L Robb, Francine E McCutchan, Jean K Carr.   

Abstract

OBJECTIVE: To further define the genetic diversity of HIV-1 in Kenya using approaches that clearly distinguish subtypes from inter-subtype recombinants.
DESIGN: Near full genome sequencing and analysis were used, including sensitive new tools for detection and mapping of recombinants.
METHODS: Purified peripheral blood mononuclear cell DNA from 41 HIV-1 positive blood donations collected from six hospitals across southern Kenya was used to amplify near full-length genomes by nested PCR. These were sequenced on an ABI 3100 automated sequencer and analyzed phylogenetically.
RESULTS: Among 41 near full-length genomes, 25 were non-recombinant (61%) and 16 were recombinant (39%). Of the 25 pure subtypes, 23 were subtype A, one was subtype C and one was subtype D. Most recombinants consisted of subtype A and either subtype C or subtype D; a few contained A2, a recently identified sub-subtype. Two A2/D recombinants had identical breakpoints and may represent a circulating recombinant form. A third A2/D recombinant had the same structure as a previously described Korean isolate, and these may constitute a second A2-containing circulating recombinant form.
CONCLUSIONS: In Kenya, 93% of HIV-1 genomes were subtype A or A-containing recombinant strains. Almost 40% of all strains were recombinant. Vaccine candidates tested in Kenya should be based on subtype A strains, but the methods used for evaluation of breakthrough infections during future vaccine trials should be capable of identifying non-A subtypes, the A2 sub-subtype, and recombinants. Copyright 2002 Lippincott Williams & Wilkins

Entities:  

Mesh:

Year:  2002        PMID: 12218394     DOI: 10.1097/00002030-200209060-00015

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  32 in total

1.  Longitudinal population analysis of dual infection with recombination in two strains of HIV type 1 subtype B in an individual from a Phase 3 HIV vaccine efficacy trial.

Authors:  David V Jobes; Melissa Daoust; Vivian T Nguyen; Allan Padua; Faruk Sinangil; Marcos Pérez-Losada; Keith A Crandall; Theodore Oliphant; David Posada; Andrew Rambaut; Jonathan Fuchs; Phillip W Berman
Journal:  AIDS Res Hum Retroviruses       Date:  2006-10       Impact factor: 2.205

2.  Sequence editing by Apolipoprotein B RNA-editing catalytic component [corrected] and epidemiological surveillance of transmitted HIV-1 drug resistance.

Authors:  Robert J Gifford; Soo-Yon Rhee; Nicolas Eriksson; Tommy F Liu; Mark Kiuchi; Amar K Das; Robert W Shafer
Journal:  AIDS       Date:  2008-03-30       Impact factor: 4.177

3.  Simultaneous detection of major drug resistance mutations in the protease and reverse transcriptase genes for HIV-1 subtype C by use of a multiplex allele-specific assay.

Authors:  Guoqing Zhang; Fangping Cai; Zhiyong Zhou; Joshua DeVos; Nick Wagar; Karidia Diallo; Isaac Zulu; Nellie Wadonda-Kabondo; Jeffrey S A Stringer; Paul J Weidle; Clement B Ndongmo; Izukanji Sikazwe; Abdoulaye Sarr; Matthew Kagoli; John Nkengasong; Feng Gao; Chunfu Yang
Journal:  J Clin Microbiol       Date:  2013-08-28       Impact factor: 5.948

4.  Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1.

Authors:  Yun Kenneth Kang; Sofija Andjelic; James M Binley; Emma T Crooks; Michael Franti; Sai Prasad N Iyer; Gerald P Donovan; Antu K Dey; Ping Zhu; Kenneth H Roux; Robert J Durso; Thomas F Parsons; Paul J Maddon; John P Moore; William C Olson
Journal:  Vaccine       Date:  2009-06-28       Impact factor: 3.641

5.  Use of sequence data generated in the Bayer Tru Gene genotyping assay to recognize and characterize non-subtype-b human immunodeficiency virus type 1 strains.

Authors:  Diane L Hirigoyen; Charles P Cartwright
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

6.  Adaptation of an R5 Simian-Human Immunodeficiency Virus Encoding an HIV Clade A Envelope with or without Ablation of Adaptive Host Immunity: Differential Selection of Viral Mutants.

Authors:  Mingkui Zhou; Michael Humbert; Muhammad M Mukhtar; Hanna B Scinto; Hemant K Vyas; Samir K Lakhashe; Siddappa N Byrareddy; Gregor Maurer; Swati Thorat; Joshua Owuor; Zhao Lai; Yidong Chen; Anthony Griffiths; Agnès-Laurence Chenine; Sanjeev Gumber; François Villinger; David Montefiori; Ruth M Ruprecht
Journal:  J Virol       Date:  2019-04-17       Impact factor: 5.103

7.  In-depth analysis of a heterosexually acquired human immunodeficiency virus type 1 superinfection: evolution, temporal fluctuation, and intercompartment dynamics from the seronegative window period through 30 months postinfection.

Authors:  F E McCutchan; M Hoelscher; S Tovanabutra; S Piyasirisilp; E Sanders-Buell; G Ramos; L Jagodzinski; V Polonis; L Maboko; D Mmbando; O Hoffmann; G Riedner; F von Sonnenburg; M Robb; D L Birx
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  The HIV-1 epidemic: low- to middle-income countries.

Authors:  Yiming Shao; Carolyn Williamson
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

9.  High-throughput high-resolution class I HLA genotyping in East Africa.

Authors:  Rebecca N Koehler; Anne M Walsh; Eric E Sanders-Buell; Leigh Anne Eller; Michael Eller; Jeffrey R Currier; Christian T Bautista; Fred Wabwire-Mangen; Michael Hoelscher; Leonard Maboko; Jerome Kim; Nelson L Michael; Merlin L Robb; Francine E McCutchan; Gustavo H Kijak
Journal:  PLoS One       Date:  2010-05-20       Impact factor: 3.240

10.  Relatively low HIV infection rates in rural Uganda, but with high potential for a rise: a cohort study in Kayunga District, Uganda.

Authors:  David Guwatudde; Fred Wabwire-Mangen; Leigh Anne Eller; Michael Eller; Francine McCutchan; Hannah Kibuuka; Monica Millard; Nelson Sewankambo; David Serwadda; Nelson Michael; Merlin Robb
Journal:  PLoS One       Date:  2009-01-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.